Search results
Results from the WOW.Com Content Network
Donepezil, sold under the brand name Aricept among others, is a medication used to treat dementia of the Alzheimer's type. [3] [4] [8] It appears to result in a small benefit in mental function and ability to function. [9] Use, however, has not been shown to change the progression of the disease. [10] Treatment should be stopped if no benefit ...
Sundowning is often a symptom that happens after someone is diagnosed with dementia or a dementia-related disease, but it can also be an early sign of mental decline itself. “There are changes ...
Paraoxon and rivastigmine are both acetylcholinesterase inhibitors and butyrylcholinesterase inhibitors. [14] [11] [7]In 2015, the United States Food and Drug Administration's Adverse Event Reporting System database compared rivastigmine to the other ChEI drugs donepezil and galantamine found that rivastigmine was associated with a higher frequency of reports of death as an adverse event.
Donepezil, which belongs to a class of medication called acetylcholinesterase inhibitors, is most commonly used to treat dementia in patients with Alzheimer's disease. Although it cannot cure Alzheimer's, it can provide patients with a better quality of life by inhibiting the loss of function and improving the ability to think. [ 20 ]
Memantine/donepezil, sold under the brand name Namzaric among others, is a fixed dose combination medication used for the treatment of dementia of the Alzheimer's type. [1] It contains memantine, as the hydrochloride, a NMDA receptor antagonist; and donepezil as the hydrochloride, an acetylcholinesterase inhibitor. [1] It is taken by mouth. [1]
Main page; Contents; Current events; Random article; About Wikipedia; Contact us
Stimulants in general and various dementia treatments [10] or other neurological therapies [11] may affect cognition. Neuroenhancement may also occur from: mood ('mood enhancement') [12] motivation [13] sociability (e.g., talking-related or empathy) [14] creativity [13] cognitive endurance [15] psychological resilience [16]
Sugimoto's research on E2020 (now called Donepezil), an acetylcholinesterase inhibitor, first began at Eisai's Tsukuba Research Laboratories in 1983, [1] because his mother suffered from dementia. [2]